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Ultra-small superparamagnetic
iron oxides for metastatic lymph
node detection: back on the block
Ansje S. Fortuin,1,2 Roger Brüggemann,3 Janine van der Linden,3 Ilia Panﬁlov,1
Bas Israël,1 Tom W.J. Scheenen1 and Jelle O. Barentsz1*
In the past 15 years, encouraging clinical results for the detection of small lymph
node metastases was obtained by the use of Combidex-enhanced MRI (CEM, also
known as magnetic resonance lymphography). Withdrawal of the European Medi-
cines Agency approval application by the manufacturer made it impossible for
patients to beneﬁt from this agent; a loss, especially for men with prostate cancer.
Current conventional imaging techniques are not as accurate as CEM is, thus a
surgical diagnostic exploration (extended lymph node dissection) is still the pre-
ferred technique to evaluate the lymph nodes, resulting in peri- and postoperative
complications. In 2013, the Radboud University Medical Center (Radboudumc)
obtained all licenses and documentation for the production process of Combidex
(ferumoxtran-10), and manufactured the contrast agent under supervision of the
Department of Pharmacy. Since 2014, 310 men with prostate cancer have been
examined with CEM in the Radboudumc. Within this cohort, seven minor possi-
bly contrast-related adverse effects were observed after administration of Combi-
dex. As the contrast agent is now back again in the Netherlands, this review
highlights the working mechanism, previous results, observed side effects since
the reintroduction, and the future perspectives for Combidex. © 2017 The Authors.
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INTRODUCTION
Knowledge of the presence of lymph node metas-tases is important to determine the prognosis
and therapy choice in cancer patients. Lymph node
status in prostate cancer patients can either be
assessed by lymphadenectomy or by imaging.
Because of the signiﬁcant limitations of availa-
ble preoperative imaging methods in the detection of
(small) lymph node metastases of prostate cancer, an
extended pelvic lymph node dissection (e-PLND) is
the gold standard to detect metastatic lymph nodes
in intermediate and high-risk prostate cancer patients
(current European guidelines1). However, this proce-
dure is invasive with a considerable complication rate
and underestimates lymph node involvement by miss-
ing small and/or distant nodes, especially in the para-
rectal and internal iliac area. Only lymph nodes
within the dissection ﬁeld are harvested, and it is
shown in a substantial percentage (60–85%) of
proven lymph node-positive patients that positive
lymph nodes were present outside the (e-)PLND
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region.2–4 Moreover, in 30% of the patients positive
lymph nodes were found only outside the (e-)PLND
region. This results not only in an underestimation of
lymph node involvement but also in a false-negative
diagnosis for the patient.2 A follow-up study sug-
gested a clinical beneﬁt of removing as many meta-
static lymph nodes as possible in comparison with
subtotal removal, as was shown in a better 5-year
survival of 80% versus 35%, respectively.5 In a
recent systematic review, however, a direct therapeu-
tic effect was not evident, and more e-PLNDs were
associated with worse intraoperative and periopera-
tive outcomes.6 They concluded that (e-)PLND was
only useful for staging. In addition, for lymph node-
negative patients, removal of lymph nodes is of no
beneﬁt to the patient, even though it puts them at
risk for the surgical complications. An accurate non-
invasive imaging technique for the detection of meta-
static lymph nodes could solve these problems.
Imaging techniques for lymph node assessment
can be divided into two groups: conventional (ana-
tomical) and functional. Both are noninvasive. Con-
ventional imaging techniques, i.e., computed
tomography (CT) and anatomical magnetic reso-
nance imaging (MRI), are widely available. These
techniques rely on size criteria to determine lymph
node status. As metastatic nodes in prostate cancer
usually are small,7–9 the sensitivity of these techni-
ques is low (30%).10 Not only in prostate cancer, but
also in other cancers like gynecological, breast, and
rectal cancer the value of size as a criterion for posi-
tive nodes is limited.11–14
Newer, functional imaging techniques rely on
hallmarks and behavior of metastatic cells in lymph
nodes or on the lymphatic drainage from the primary
tumor to surrounding lymph nodes.15 Different func-
tional techniques have been investigated for prostate
cancer. Choline positron emission tomography–CT
(PET-CT) appeared to be suitable for the detection of
larger lymph node metastases but is unsatisfactory
for nodes smaller than 7 mm.7 In recurrent prostate
cancer, choline, PET-CT may have some added
value, but in primary intermediate- to high-risk pros-
tate cancer its sensitivity is poor (49%).16,17
Recently, promising results have been shown
for 68Ga-labeled prostate-speciﬁc membrane antigen
(PSMA) ligand PET-CT. This technique appears
superior to choline PET-CT for small lymph nodes18
and lower Prostate-speciﬁc antigen (PSA) levels.19 A
recent meta-analysis for 68Ga-PSMA PET included
16 articles involving 1309 patients. Summary sensi-
tivity and speciﬁcity on a per-patient basis were both
86%. On a per-lesion analysis, summary sensitivity
and speciﬁcity were 80% and 97%, respectively.20
The overall percentage of positive scans was higher
for patients with biochemical recurrence than for
patients with primary disease (76% vs 40%), and
68Ga-PSMA PET-CT positive patients had higher
prescan PSA levels. But even with improved tumor
speciﬁcity these new tracers appear not to be capable
of reliably detecting metastatic lymph nodes below
5 mm in size,21,22 as the median size of missed nodal
metastases with 68Ga-PSMA PET/CT was 4.3 mm.23
A disadvantage of PSMA ligands is uptake in other
organs such as the kidney, small bowel loops, sali-
vary glands, ureters, and the urinary bladder.24 Fur-
thermore, reports are accumulating on uptake of the
tracer in other cancers or benign conditions, like sar-
coidosis and inﬂammation.25–36
Since the beginning of the 1990s, encouraging
results have been shown for Combidex-enhanced
MRI (CEM, also known as magnetic resonance lym-
phography). Combidex is a solution of iron oxide
particles coated with dextran, which is slowly intra-
venously administered in patients 24–36 h prior to
MRI. The ultra-small superparamagnetic iron oxide
(USPIO) particles are internalized by macrophages,
which accumulate in normal lymph nodes. On iron-
sensitive MR-images, these normal nodes lose MR
signal and are black, whereas metastatic lymph nodes
remain white.8 Moreover, MRI provides anatomical
soft-tissue contrast with a high spatial resolution. In
comparison with lymphadenectomy, MRI can visual-
ize nodes in the entire pelvis, upper abdomen, and
the rest of the body, and can therefore identify posi-
tive lymph nodes outside the routine surgical ﬁeld.2
Unfortunately, in 2009, Combidex was with-
drawn from the registration process in Europe by the
manufacturer. An alternative agent with iron oxide
nanoparticles, Feraheme (ferumoxytol; AMAG
Pharma, Waltham, MA, USA), was approved for ther-
apeutic use as intravenous iron replacement therapy in
anemia, and was used off-label as an alternative for
Combidex.37 However, in March 2015, the Food and
Drug Administration (FDA) issued a ‘Boxed Warning’
regarding serious risks for Feraheme because of associ-
ation with fatal anaphylaxis.38,39 In addition, the ‘dar-
kening’ of normal nodes with Feraheme did not
appear as prominent as with Combidex, even with tri-
ple doses of iron oxide,40 resulting in inferior diagnos-
tic quality compared with Combidex.
In 2013, the Radboud University Medical Cen-
ter (Radboudumc) obtained all rights and documents
regarding Combidex, and was able to manufacture
the contrast agent again, exactly according to original
speciﬁcations and under supervision of an accredited
pharmacy. In 2015, all the rights were transferred to
SPL Medical B.V. in Nijmegen, The Netherlands,
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who is currently the only rights owner and manufac-
turer of Combidex. With the availability of the agent
in clinical practice in the Netherlands, the time is right
to review its working mechanism and results from
earlier studies. Furthermore, the reintroduction of
Combidex, its clinical use, and side effects because of
the reintroduction are described, together with the
future perspectives for the contrast agent.
USPIO-ENHANCED MRI: WORKING
MECHANISM OF COMBIDEX
Combidex is a solution of dextran-coated iron oxide
nanoparticles (size 20–50 nm) intravenously adminis-
tered with a slow-drip infusion (30 min) to the
patient 24–36 h prior to MRI imaging. These
nanoparticles are ingested by macrophages, which
accumulate in normal lymph nodes throughout the
body. Metastatic lymph nodes will not pick up the
iron nanoparticles (Figure 1(a) and (b)). Benign and
metastatic lymph nodes can therefore be differen-
tiated on an iron-sensitive (T2*-weighted) MRI
sequence 24–36 h after administration of Combidex.
Normal lymph nodes are black on these MR-images,
whereas nodes with metastases are white, retaining
MR signal.41 This is an indirect functional imaging
technique: it does not rely on minimal uptake in via-
ble tumor tissue, and there is no issue with back-
ground uptake in organs. In a T1-weighted MRI
image series after the infusion of Combidex, the anat-
omy of vessels and nodes can be depicted (Figure 1
(c)). Two pelvic lymph nodes would have been con-
sidered normal using MRI without Combidex. With
(a)
Metastasis
Normal
Metastasis
Normal
Metastasis
Normal
Metastasis
Normal
(b)
(c) (d)
FIGURE 1 | Mechanism of action of Combidex-enhanced magnetic resonance imaging (MRI). In normal (parts of ) healthy lymph nodes iron
oxide nanoparticles accumulate (a), whereas metastases contain less nanoparticles 24–36 h after Combidex administration. In iron-sensitive MRI
scans, the nanoparticles cause the MR signal to disappear, while metastatic (parts of ) lymph nodes retain MRI signal (b). On the T1-weighted
Combidex image of a patient with metastasized prostate cancer, two nodes (circles) are visible close to the obturator nerve (arrow in c). Both their
sizes are normal. On the T2*-weighted iron-sensitive image, one of these nodes is black because of the presence of iron oxide nanoparticles, and
thus is normal (left circle in d), whereas the metastatic node retained MR signal intensity and is white (right circle in d). Because of its position,
2 cm behind the obturator nerve, the metastatic node would not be removed during a typical pelvic lymph node dissection.
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CEM, a clear-cut distinction is seen between the nor-
mal node (black), and the node almost totally replaced
with metastatic prostate cancer (Figure 1(d), node
almost all white).
USPIO-ENHANCED MRI: EARLIER
RESULTS OF COMBIDEX
In the last 15 years, encouraging clinical results for
CEM in patient use were shown with a pooled sensi-
tivity of 90% and a pooled speciﬁcity of 96% for
several types of cancer,42 including prostate cancer.
The largest study with Combidex in prostate cancer
was performed in 375 patients reporting sensitivity
and speciﬁcity for the detection of lymph node metas-
tasis of 82% and 93%, respectively, with histopa-
thology of extended resections or guided lymph node
biopsies as gold standard.43 All the studies evaluating
CEM in prostate cancer were performed with an
MRI system at a magnetic ﬁeld strength of 1.5 T. A
study comparing image quality of CEM at 1.5 T with
3.0 T showed improvements at the higher ﬁeld
strength,44 but the study was not designed to com-
pare the detection of (small) metastatic lymph nodes.
A Swiss research group published CEM studies com-
bining prostate and bladder cancer using a ﬁeld
strength of 3 T.45–47 Their speciﬁcity of metastatic
lymph node detection (87–96%) was in agreement
with earlier results, but their sensitivity (65–80%) was
lower, probably because of the use of a T2-weighted,
rather than a T2*-weighted MRI sequence.48
Added clinical value of CEM was revealed in
studies that showed positive lymph nodes outside the
standard pelvic lymph node dissection area2 and
standard radiation ﬁeld49,50 in a substantial number
of patients (53–79%). A recent whole body MRI
study for the assessment of metastatic spread in pros-
tate cancer underlined these ﬁndings.4 With CEM an
underestimation of metastatic disease, and conse-
quent mismatch in treatment, can be avoided.
Several CEM studies emphasized the capability
of ﬁnding metastases in normal-sized lymph
nodes.7,8,45,49 This is a major step forward compared
with conventional and established functional imaging
techniques. Detecting small lymph node metastases
or detecting limited metastatic disease provides
opportunities for more patient-tailored therapy. With
CEM as a technique to (re)deﬁne oligometastatic dis-
ease, these therapies might even be given with cura-
tive intent.4,5,51,52
Furthermore, knowledge on size of lymph node
metastases can help predict prognosis. Patients with
nodal metastases ≤8 mm versus larger nodal
metastases have a signiﬁcantly better 5-year
metastasis-free survival (79% vs 16%) and overall
survival (81% vs 36%).5 CEM can help to identify
these small positive lymph nodes as the technique
enables detection of (pathologic) lymph nodes as
small as 2 mm.7
USPIOs BACK ON THE BLOCK:
REINTRODUCTION PROCESS OF
COMBIDEX
At present time, there is no alternative contrast agent
or medical device that yields similar clinical results as
CEM for detection of small metastatic lymph nodes
in prostate2,7,8,15,43,44,49–51,53–59 and other cancers.42
Radboudumc therefore decided to revive the produc-
tion of Combidex and obtained all documents and
rights for Combidex from its previous manufacturer,
AMAG Pharma.
The ﬁrst four production batches of Combidex
for clinical patient use (intended for Radboudumc
patients only) were produced and used as a legiti-
mate exception of National and European Union
(EU) legislation.60 Requirements for this category of
products are presence of a sound rationale to use
the product (motivation and justiﬁcation of clinical
need), lack of alternative medication with a market-
ing authorization, and preparation and control
according to the European or National Pharmaco-
poeia.61 The drug has to be a medicinal product
manufactured and supplied directly to the patients
served by the pharmacy in question.60 The produc-
tion of Combidex was outsourced to qualiﬁed and
authorized companies [good manufacturing practice
(GMP) production] under the supervision of the
Department of Pharmacy of Radboudumc under
Dutch law (Dutch Medicines Act and Directive
2001/83/EC). The department instituted a control
process by performing audits and reviewing the
required validation and stability protocols and
reports. Speciﬁcations of Combidex regarding
appearance, iron-, dextran-, citrate content, particle
size, magnetic susceptibility, clustering of particles,
pH value, sterility, endotoxins, and bioburden were
reviewed by the qualiﬁed person of the Pharmacy
Department of Radboudumc, who released the ﬁnal
product.
In 2015, all the rights were transferred to SPL
Medical B.V. in Nijmegen, The Netherlands, who is
currently the only rights owner and the only manu-
facturer of Combidex, and produces Combidex
under GMP conditions.
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CLINICAL USE OF COMBIDEX IN
PROSTATE CANCER PATIENTS
SINCE 2014
In 2014, Radboudumc launched ‘nano-MRI,’ rein-
troducing CEM in patients with prostate cancer.
Between January 2014 and July 2016, 310 men,
with intermediate to high risk for lymph node
metastases or suspicious for recurrent disease,
underwent a 3-T MRI after intravenous Combidex
administration in our hospital (e.g., in Figure 2).
Thirty of these patients underwent nano-MRI twice.
Demographic data of the patients are presented in
Table 1.
Patients were administered 2.6 mg Fe/kg Com-
bidex, diluted in 100 mL 0.9% sodium chloride
using a Minisart NML 0.22 μm pore size ﬁlter (Min-
isart NML Syringe Filters 16534-k; Sartorius AG,
Goettingen, Germany). Combidex was intravenously
infused over at least 30 min. At the start of the
infusion, a very slow infusion rate of 1 mL/min was
used, which was increased after 5 min to an average
infusion rate of 4 mL/min.
For patient safety, the contrast was given with
direct access to supportive agents in case of severe or
serious contrast reactions. A radiologist supervised
each contrast administration procedure from the start
of infusion until approximately 30 min after
FIGURE 2 | Nano-magnetic resonance imaging (MRI) (Combidex-enhanced MRI) at 3 T of a 53-year-old patient with recurrent prostate cancer
after radical prostatectomy and radiotherapy (posttherapy PSA-level 3.9 ng/mL). Twenty-seven hours after administration of Combidex, metastatic
lymph nodes remain white on the three-dimensional (3D) iron-sensitive MR-images in contrast to benign lymph nodes who become black. A large
(7 mm) metastatic lymph node was visible on nano-MRI as a white spherical structure in two orthogonal planes through the node [blue circles in
coronal (a) and axial images (b)]. A smaller metastatic white node (2 mm) is indicated with red circles in the coronal (c) and axial
(d) reconstructions (orthogonal planes through the node of interest) of the 3D data set. The other small spherical structures are blood vessels, best
appreciated when scrolling through the 3D image data set. Parameters: 3D T2*-weighted MRI with echo time 12 ms (two combined echoes),
resolution 0.85 × 0.85 × 0.85 mm, acquisition time 10:10 min.
TABLE 1 | Demographics of 310 Prostate Cancer Patients Studied
with Nano-Magnetic Resonance Imaging (January 2014–July 2016)
Age (mean/median) 64.7/65.0 years
Weight (mean/median) 84.8/83.5 kg
Patients with prior allergic reactions 7.4%
Patients with prior contrast reactions
(iodine)
1.0%
Newly diagnosed patients 14.8%
Patients with PSA recurrence after therapy 85.2%
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completion. If an adverse event was observed by the
radiologist or reported by the patient, appropriate
action was taken. Twenty-four to 36 h later, when
the patients returned for the MRI scan, patients were
asked again about the occurrence of any adverse side
effects. All adverse events were assessed by the radi-
ologist and stratiﬁed into ﬁve grades according to the
Common Terminology Criteria for Adverse Events,62
and noted in the patient’s ﬁle and in a separate
locked research database.
The radiologist made the judgment if the adverse
effect was Combidex-related. Technically, all nano-
MRI examinations were successful and of good qual-
ity, showing loss of MR signal because of Combidex
in healthy lymph nodes in all patients, and showing
white lymph nodes indicating metastases (Figure 2).
Adverse Effects
Eight of 310 patients (2.6%) had adverse effects.
Seven of these patients (2.3%) were judged deﬁnitely
(4) or possibly (3) contrast-related. In four of these
patients, the effects occurred during the beginning of
the infusion (minor low back pain, ﬂushing, and nau-
sea). The infusion was temporarily discontinued in
these patients whereupon the complaints disap-
peared. After several minutes, the infusion was
restarted slowly and could be ﬁnished without any
further complications. The other three patients com-
plained of a dry mouth directly after completion of
Combidex infusion. This disappeared in all before
they left the department. As no treatment or interven-
tion was needed, the adverse events were stratiﬁed as
Grade 1 (Table 2).
Additionally, one patient with Cushing’s dis-
ease had an acute adrenal crisis 2 h after Combidex
infusion. He was treated successfully by outpatient
care. The next day he underwent an uneventful
nano-MRI. The adrenal crisis was considered stress-
related, and not contrast agent-related.
In 2009, Bernd et al. reported safety data of
37 clinical trials with in total 1663 patients who
received Combidex.63 Adverse events were reported
in 23% of patients subdivided into Grade 1 mild
(55%), Grade 2 moderate (30%), Grade 4 severe
(12%), and Grade 5 serious (3%).
Low back pain, ﬂushing, and nausea (Table 2)
occurred also in the earlier studies. The dry mouth
reported in three of our patients was not reported
before, but as it appeared immediately after the infu-
sion was completed, it was considered possibly
contrast-related. The absence of moderate or serious
(Grades 2–5) Combidex-related adverse events in the
current cohort is in agreement with a cohort study
performed by our institute, published in 2008,43
where only mild (Grade 1) adverse events occurred in
21 of 375 (6%) patients. The explanation may be the
similar way of the infusion: always diluted, very slow
at the start, with immediate discontinuation of the
infusion upon complaints. In the current study, we
also added a ﬁlter in the infusion line.
FUTURE PERSPECTIVES FOR
COMBIDEX
The Radboudumc spin-off company SPL Medical
B.V. was set up in 2015 with the aim to promote
and to register Combidex in different regions in the
world, and to make it available for as many patients as
possible. Next to clinical use in prostate cancer patients
in Radboudumc, clinical research is planned with the
use of CEM in other types of cancer.
Recently our group succeeded in high-
resolution MR imaging of pelvic lymph nodes at a
magnetic ﬁeld strength of 7 T.64 Lymph nodes were
clearly identiﬁable down to sizes of 1.5 mm. This
opens possibilities for detection of even smaller meta-
static lymph nodes with CEM at 7 T. Apart from
oncologic applications, Combidex has shown value in
preliminary studies in a multitude of diseases; promis-
ing applications that now can be explored again.
CONCLUSION
Radboudumc successfully reintroduced Combidex-
enhanced MRI as nano-MRI, and currently uses it
in patients with prostate cancer to detect small meta-
static lymph nodes. A total of 310 patients had
Combidex administered using a very slow drip infu-
sion, and only in 2.6% of these patients mild Grade
1 Combidex-related or possibly Combidex-related
adverse events occurred. The good safety proﬁle and
the rebirth of Combidex provide new opportunities
for lymph node staging in patients with prostate
cancer, and opens up possibilities for patients with
other cancers and other diseases.
TABLE 2 | Patients with Combidex Administration-Related Adverse
Events
Type of Adverse Event,
All Were Grade 1 Number of Patients
Back pain 2/310 (contrast-related)
Nausea 1/310 (contrast-related)
Flushing/feeling hot 1/310 (contrast-related)
Dry mouth 3/310 (possibly contrast-related)
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